Jon Stoessl

Summary

Affiliation: University of British Columbia
Country: Canada

Publications

  1. ncbi request reprint Treatment for the progression of Parkinson's disease
    Donald Calne
    Pacific Parkinson s Research Centre UBC, Vancouver, British Columbia, Canada
    Lancet Neurol 4:206. 2005
  2. doi request reprint Milestones in neuroimaging
    A Jon Stoessl
    Pacific Parkinson s Research Centre, University of British Columbia and Vancouver Coastal Health, Vancouver, British Columbia, Canada
    Mov Disord 26:868-978. 2011
  3. doi request reprint Functional imaging studies of non-motoric manifestations of Parkinson's Disease
    A Jon Stoessl
    Pacific Parkinson s Research Centre, University of British Columbia and Vancouver Coastal Health, Vancouver, BC, Canada
    Parkinsonism Relat Disord 15:S13-6. 2009
  4. ncbi request reprint Willing oneself better on placebo--effective in its own right
    A Jon Stoessl
    Pacific Parkinson s Research Centre, University of British Columbia, Vancouver, BC, Canada V6T 2B5
    Lancet 364:227-8. 2004
  5. ncbi request reprint Agonizing over dopaminergic replacement therapy--lessons from animal models of Parkinson's disease
    A Jon Stoessl
    Pacific Parkinson s Research Centre, University of British Columbia, 2221 Wesbrook Mall, Vancouver, BC, Canada V6T 2B5
    Exp Neurol 183:1-3. 2003
  6. doi request reprint Positron emission tomography in premotor Parkinson's disease
    A Jon Stoessl
    Pacific Parkinson s Research Centre, University of British Columbia and Vancouver Coastal Health, 2221 Wesbrook Mall, Vancouver, BC, Canada V6T 2B5
    Parkinsonism Relat Disord 13:S421-4. 2007
  7. pmc Neuroimaging in Parkinson's disease
    A Jon Stoessl
    Pacific Parkinson s Research Centre, University of British Columbia and Vancouver Coastal Health, Vancouver, British Columbia, Canada
    Neurotherapeutics 8:72-81. 2011
  8. ncbi request reprint Potential therapeutic targets for Parkinson's disease
    Jon Stoessl
    University of British Columbia and Vancouver Coastal Health, Pacific Parkinson s Research Centre and National Parkinson Foundation Centre of Excellence, 2221 Wesbrook Mall, Vancouver, BC, V6T 2B5, Canada
    Expert Opin Ther Targets 12:425-36. 2008
  9. ncbi request reprint Gene therapy for Parkinson's disease: early data
    A Jon Stoessl
    Pacific Parkinson s Research Centre, University of British Columbia, Vancouver, BC, Canada V6T 2B5
    Lancet 369:2056-8. 2007
  10. doi request reprint Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease
    Ramachandiran Nandhagopal
    Pacific Parkinson s Research Centre, University of British Columbia and Vancouver Coastal Health, Vancouver, BC V6T 2B5, Canada
    Brain 134:3290-8. 2011

Detail Information

Publications59

  1. ncbi request reprint Treatment for the progression of Parkinson's disease
    Donald Calne
    Pacific Parkinson s Research Centre UBC, Vancouver, British Columbia, Canada
    Lancet Neurol 4:206. 2005
  2. doi request reprint Milestones in neuroimaging
    A Jon Stoessl
    Pacific Parkinson s Research Centre, University of British Columbia and Vancouver Coastal Health, Vancouver, British Columbia, Canada
    Mov Disord 26:868-978. 2011
    ....
  3. doi request reprint Functional imaging studies of non-motoric manifestations of Parkinson's Disease
    A Jon Stoessl
    Pacific Parkinson s Research Centre, University of British Columbia and Vancouver Coastal Health, Vancouver, BC, Canada
    Parkinsonism Relat Disord 15:S13-6. 2009
    ..This article will review non-motor aspects of PD. While there is an enormous volume of imaging literature on the motor aspects of PD or motoric complications, that will not be addressed here...
  4. ncbi request reprint Willing oneself better on placebo--effective in its own right
    A Jon Stoessl
    Pacific Parkinson s Research Centre, University of British Columbia, Vancouver, BC, Canada V6T 2B5
    Lancet 364:227-8. 2004
  5. ncbi request reprint Agonizing over dopaminergic replacement therapy--lessons from animal models of Parkinson's disease
    A Jon Stoessl
    Pacific Parkinson s Research Centre, University of British Columbia, 2221 Wesbrook Mall, Vancouver, BC, Canada V6T 2B5
    Exp Neurol 183:1-3. 2003
  6. doi request reprint Positron emission tomography in premotor Parkinson's disease
    A Jon Stoessl
    Pacific Parkinson s Research Centre, University of British Columbia and Vancouver Coastal Health, 2221 Wesbrook Mall, Vancouver, BC, Canada V6T 2B5
    Parkinsonism Relat Disord 13:S421-4. 2007
    ..An interesting potential application of PET is the determination of non-dopaminergic abnormalities that correlate with the presence of clinically apparent pre-motor symptoms of PD...
  7. pmc Neuroimaging in Parkinson's disease
    A Jon Stoessl
    Pacific Parkinson s Research Centre, University of British Columbia and Vancouver Coastal Health, Vancouver, British Columbia, Canada
    Neurotherapeutics 8:72-81. 2011
    ..A number of clinical applications are highlighted, including diagnostic utility, identification of preclinical disease, changes associated with motor and nonmotor complications of PD, and the effects of various therapeutic interventions...
  8. ncbi request reprint Potential therapeutic targets for Parkinson's disease
    Jon Stoessl
    University of British Columbia and Vancouver Coastal Health, Pacific Parkinson s Research Centre and National Parkinson Foundation Centre of Excellence, 2221 Wesbrook Mall, Vancouver, BC, V6T 2B5, Canada
    Expert Opin Ther Targets 12:425-36. 2008
    ..The most important gap is the availability of treatments that modify the inexorable progression of disease or that could prevent its onset in subjects at risk...
  9. ncbi request reprint Gene therapy for Parkinson's disease: early data
    A Jon Stoessl
    Pacific Parkinson s Research Centre, University of British Columbia, Vancouver, BC, Canada V6T 2B5
    Lancet 369:2056-8. 2007
  10. doi request reprint Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease
    Ramachandiran Nandhagopal
    Pacific Parkinson s Research Centre, University of British Columbia and Vancouver Coastal Health, Vancouver, BC V6T 2B5, Canada
    Brain 134:3290-8. 2011
    ..Our data suggest that compensatory mechanisms decline as Parkinson's disease progresses. This breakdown of compensatory strategies in the putamen could contribute to the progression of motor symptoms in advanced disease...
  11. ncbi request reprint Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications
    Vesna Sossi
    University of British Columbia, Vancouver, Canada
    Brain 129:1050-8. 2006
    ..These results provide one possible explanation for the age-dependent occurrence of complications and support the existence of a pre-synaptic contribution to the occurrence of motor complications...
  12. ncbi request reprint Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms
    Vesna Sossi
    Departments of Physics and Astronomy and Neurology, University of British Columbia, Vancouver, Canada
    J Cereb Blood Flow Metab 24:869-76. 2004
    ....
  13. ncbi request reprint Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias
    Raul de la Fuente-Fernandez
    Pacific Parkinson s Research Centre, University of British Columbia, Vancouver, BC, Canada
    Brain 127:2747-54. 2004
    ..Large levodopa-induced increases in synaptic dopamine concentration can lead to dramatic changes in receptor occupancy, which may be responsible for the emergence of peak-dose dyskinesias in Parkinson's disease...
  14. ncbi request reprint PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation
    John R Adams
    Pacific Parkinson s Research Centre, TRIUMF, Vancouver, BC, Canada
    Brain 128:2777-85. 2005
    ..Furthermore, we suggest that compensatory changes including downregulation of the DAT and upregulation of decarboxylase activity may delay the onset of parkinsonian symptoms...
  15. doi request reprint Effects of expectation on placebo-induced dopamine release in Parkinson disease
    Sarah C Lidstone
    Pacific Parkinson s Research Centre, University of British Columbia, Vancouver, British Columbia, Canada
    Arch Gen Psychiatry 67:857-65. 2010
    ..In Parkinson disease (PD), the placebo effect is associated with release of endogenous dopamine in both nigrostriatal and mesoaccumbens projections, yet the factors that control this dopamine release are undetermined...
  16. ncbi request reprint VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET
    Raul de la Fuente-Fernandez
    Pacific Parkinson s Research Centre, University of British Columbia, Vancouver, B C, Canada
    Synapse 49:20-8. 2003
    ..This is in keeping with a role for VMAT2 in other cellular processes (i.e., sequestration and release from the cell of potential toxic products), in addition to its importance for the quantal release of monoamines...
  17. doi request reprint Visualizing vesicular dopamine dynamics in Parkinson's disease
    Raul de la Fuente-Fernandez
    Pacific Parkinson s Research Centre, University of British Columbia, Vancouver, British Columbia, Canada
    Synapse 63:713-6. 2009
    ..Endogenous dopamine and exogenously derived dopamine seem to follow the same vesicular dynamics...
  18. ncbi request reprint [11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease
    Ajit Kumar
    Pacific Parkinson s Research Centre, Vancouver Hospital and Health Sciences Centre, Vancouver, BC, Canada
    Brain 126:2648-55. 2003
    ..Therefore, our study suggests that both levodopa treatment and DA terminal loss contribute to the pathogenesis of motor fluctuations...
  19. ncbi request reprint Placebo mechanisms and reward circuitry: clues from Parkinson's disease
    Raul de la Fuente-Fernandez
    Pacific Parkinson s Research Centre, University of British Columbia, Vancouver, British Columbia, Canada
    Biol Psychiatry 56:67-71. 2004
    ..The magnitude of the placebo effect likely depends on the a priori probability of clinical benefit. This notion has profound implications in the design of clinical trials and placebo investigations...
  20. doi request reprint Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's: an in vivo imaging study
    Vesna Sossi
    Pacific Parkinson s Research Centre, Wesbrook Mall, Vancouver, British Columbia, Canada
    J Neurochem 109:85-92. 2009
    ....
  21. ncbi request reprint Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis
    Chong S Lee
    Pacific Parkinson s Research Centre, Vancouver Hospital and Health Sciences Centre, 2221 Wesbrook Mall, Purdy Pavilion Room M36, Vancouver, British Columbia, Canada V6T 2B5
    Arch Neurol 61:1920-5. 2004
    ..Dopamine terminal loss in the putamen of patients with Parkinson disease (PD) shows a regional heterogeneity, reflecting selective vulnerability of degenerating neurons to mechanisms of cell death...
  22. ncbi request reprint Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: positron emission tomographic studies
    Kaveh M Koochesfahani
    Pacific Parkinson s Research Centre, University of British Columbia, Vancouver, British Columbia, Canada
    Mov Disord 21:970-5. 2006
    ..Our data provide in vivo neurochemical support for the lack of clinical efficacy following MP in PD patients and are also in keeping with reduced DA release following amphetamine in PD subjects...
  23. doi request reprint Dopamine transporter PET in normal aging: dopamine transporter decline and its possible role in preservation of motor function
    Andre R Troiano
    Pacific Parkinson s Research Centre, University of British Columbia, Vancouver, British Columbia, Canada
    Synapse 64:146-51. 2010
    ..To determine the impact of age-related decline in dopamine transporter (DAT) expression on motor function in the elderly...
  24. ncbi request reprint Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model
    Raul de la Fuente-Fernandez
    Pacific Parkinson s Research Centre, University of British Columbia, Vancouver, BC V6T 2B5, Canada
    Brain 127:888-99. 2004
    ..The model supports the idea that presynaptic mechanisms play a key role in both short-duration and long-duration responses encountered in Parkinson's disease. Dyskinesias may also be explained by the same mechanisms...
  25. doi request reprint Age-specific progression of nigrostriatal dysfunction in Parkinson's disease
    Raul de la Fuente-Fernandez
    Pacific Parkinson s Research Centre, University of British Columbia, Vancouver, BC, Canada
    Ann Neurol 69:803-10. 2011
    ..To investigate in vivo the impact of age on nigrostriatal dopamine dysfunction in Parkinson's disease (PD)...
  26. ncbi request reprint Age and severity of nigrostriatal damage at onset of Parkinson's disease
    Raul de la Fuente-Fernandez
    Pacific Parkinson s Research Centre, and TRIUMF, University of British Columbia, Vancouver, BC, Canada V6T 2B5
    Synapse 47:152-8. 2003
    ..Age-related differences in [(18)F]-dopa uptake may be related to changes in dopamine turnover...
  27. ncbi request reprint Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation
    Rodrigo Mercado
    Surgical Centre for Movement Disorders, University of British Columbia, British Columbia, Canada
    Mov Disord 21:1457-61. 2006
    ..The results presented support the role of expectation and placebo effects in STN-DBS in Parkinson's disease patients...
  28. ncbi request reprint Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study
    Vesna Sossi
    University of British Columbia, Vancouver, British Columbia, Canada
    Ann Neurol 62:468-74. 2007
    ..To investigate the role of the dopamine transporter (DAT) in the regulation of synaptic dopamine (DA) levels in Parkinson's disease and its role in the preservation of DA in presynaptic terminals...
  29. ncbi request reprint [18F]-Dopa positron emission tomography imaging in early-stage, non-parkin juvenile parkinsonism
    Pramod K Pal
    Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, British Columbia, Canada
    Mov Disord 17:789-94. 2002
    ..Extensive DNA analysis in this patient did not show mutations in the parkin gene...
  30. ncbi request reprint Parkinson's disease: in vivo assessment of disease progression using positron emission tomography
    Wing Lok Au
    Pacific Parkinson s Research Centre, University of British Columbia, Vancouver Hospital and Health Sciences Centre, Purdy Pavilion, 2221 Wesbrook Mall, Vancouver, BC, Canada V6T 2B5
    Brain Res Mol Brain Res 134:24-33. 2005
    ..In this review, we shall discuss some of the issues and concerns that arise with the use of PET as a surrogate marker of disease progression in Parkinson's disease...
  31. ncbi request reprint Understanding the placebo effect: contributions from neuroimaging
    Sarah C Christine Lidstone
    Pacific Parkinson s Research Centre and Graduate Program in Neuroscience, University of British Columbia, Vancouver, British Columbia, Canada
    Mol Imaging Biol 9:176-85. 2007
    ..Understanding the mechanisms of the placebo effect has important implications for treatment of several medical conditions, including depression, pain, and Parkinson's disease...
  32. ncbi request reprint Dopamine release in human ventral striatum and expectation of reward
    Raul de la Fuente-Fernandez
    Pacific Parkinson s Research Centre, Vancouver Hospital and Health Sciences Center, University of British Columbia, Purdy Pavilion, 2221 Westbrook Mall, Vancouver, BC, Canada V6T 2B5
    Behav Brain Res 136:359-63. 2002
    ..These observations have potential implications for the treatment of drug addiction...
  33. ncbi request reprint Positron emission tomography after fetal transplantation in Huntington's disease
    Sarah Furtado
    Pacific Parkinson s Research Centre, University of British Columbia, Vancouver, British Columbia, Canada
    Ann Neurol 58:331-7. 2005
    ..These findings may reflect loss of graft viability and/or disease progression. There was no significant relationship between changes in PET and clinical function. In summary, there was no benefit from transplantation...
  34. ncbi request reprint The biochemical bases for reward. Implications for the placebo effect
    Raul de la Fuente-Fernandez
    Pacific Parkinson s Research Centre, University of British Columbia
    Eval Health Prof 25:387-98. 2002
    ..g., opioid release in placebo analgesia; serotonin regulation in response to placebo antidepressants). In addition, placebos may have a role in substitution programs for the treatment of drug addiction...
  35. pmc Leg muscle strength is reduced in Parkinson's disease and relates to the ability to rise from a chair
    Lisa M Inkster
    School of Rehabilitation Sciences, University of British Columbia, Vancouver, British Columbia, Canada
    Mov Disord 18:157-62. 2003
    ..Reduced strength, particularly at the hip, may be one factor that contributes to the difficulty of persons with PD to rise from a chair...
  36. ncbi request reprint The placebo effect in Parkinson's disease
    Raul de la Fuente-Fernandez
    Pacific Parkinson s Research Centre, University of British Columbia, Purdy Pavilion, 2221 Wesbrook Mall, Vancouver, BC, Canada V6T 2B5
    Trends Neurosci 25:302-6. 2002
    ..Other neurotransmitters or neuropeptides, however, are also likely to be involved in mediating the placebo effect (e.g. opioids in pain disorders, serotonin in depression)...
  37. ncbi request reprint PET study of [(18)F]6-fluoro-L-dopa uptake in neuroleptic- and mood-stabilizer-naive first-episode nonpsychotic mania: effects of treatment with divalproex sodium
    Lakshmi N Yatham
    Department of Psychiatry, University of British Columbia, Vancouver, Canada
    Am J Psychiatry 159:768-74. 2002
    ....
  38. ncbi request reprint Parkinson's disease: imaging update
    Raul de la Fuente-Fernandez
    Pacific Parkinson s Research Centre, University of British Columbia, Purdy Pavilion, 2221 Wesbrook Mall, Vancouver, British Columbia, Canada V6T 2B5
    Curr Opin Neurol 15:477-82. 2002
    ..We aim to review recent neuroimaging contributions to our understanding of the cause and pathogenesis of Parkinson's disease, as well as treatment-related complications of disease, with a focus on functional anatomy and neurochemistry...
  39. ncbi request reprint PET study of the effects of valproate on dopamine D(2) receptors in neuroleptic- and mood-stabilizer-naive patients with nonpsychotic mania
    Lakshmi N Yatham
    Mood Disorders Clinical Research Unit, University of British Columbia, 2255 Wesbrook Mall, Vancouver, BC, Canada V6T 2A1
    Am J Psychiatry 159:1718-23. 2002
    ..The purpose of this study was to further examine D(2) receptor density in a larger sample of nonpsychotic manic patients by using positron emission tomography (PET) and [(11)C]raclopride...
  40. ncbi request reprint Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitization to levodopa
    J M Van Kampen
    Pacific Parkinson s Research Centre, 2221 Wesbrook Mall Rm M36, University of British Columbia, Vancouver, BC V6T 2B5, Canada
    Neuroscience 116:307-14. 2003
    ....
  41. doi request reprint Functional imaging in Parkinson disease
    R Nandhagopal
    Pacific Parkinson s Research Center, University of British Columbia, Vancouver Hospital and Health Sciences Center, Purdy Pavilion, 2221 Wesbrook Mall, Vancouver, BC, Canada
    Neurology 70:1478-88. 2008
    ..Here, the authors review the various approaches and potential application of these imaging techniques to the study of PD...
  42. ncbi request reprint Clustering of Parkinson disease: shared cause or coincidence?
    Ajit Kumar
    Pacific Parkinson s Research Centre, Vancouver Hospital and Health Sciences Centre, University of British Columbia, 2221 Wesbrook Mall, Vancouver, BC, Canada V6T 2B5
    Arch Neurol 61:1057-60. 2004
    ..The spatial and temporal pattern of excessive disease occurrence, termed clustering, may provide clues about the underlying etiology...
  43. ncbi request reprint Etiology of Parkinson's disease
    Zhigao Huang
    Pacific Parkinson s Research Centre, University of British Columbia, Vancouver, BC, Canada
    Can J Neurol Sci 30:S10-8. 2003
    ..We review the various genetic and environmental factors thought to be involved in PD, as well as the mechanisms that contribute to selective nigral cell death...
  44. ncbi request reprint The placebo effect in neurological disorders
    Raul de la Fuente-Fernandez
    Pacific Parkinson s Research Centre, University of British Columbia, BC, Vancouver, Canada
    Lancet Neurol 1:85-91. 2002
    ..We also discuss the evidence for the use of placebos in long-term substitution programmes for the treatment of drug addiction...
  45. ncbi request reprint Dopamine receptors in Parkinson's disease: imaging studies
    A Jon Stoessl
    Pacific Parkinson s Research Centre, University of British Columbia, Vancouver, British Columbia, Canada
    Adv Neurol 91:65-71. 2003
  46. ncbi request reprint Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study
    Alan L Whone
    Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom
    Ann Neurol 54:93-101. 2003
    ..1%; levodopa, -22.9%; 95% CI, 4.24-13.3), but the decrease was significantly lower with ropinirole compared with levodopa (p < 0.001). Ropinirole is associated with slower progression of PD than levodopa as assessed by (18)F-dopa PET...
  47. ncbi request reprint Neural transplantation for the treatment of Parkinson's disease
    Anders Bjorklund
    Wallenberg Neuroscience Center, Section of Neurobiology, Lund University, Sweden
    Lancet Neurol 2:437-45. 2003
  48. ncbi request reprint A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Ann Neurol 54:403-14. 2003
    ..Fetal nigral transplantation currently cannot be recommended as a therapy for PD based on these results...
  49. ncbi request reprint The biochemical bases of the placebo effect
    Raul de la Fuente-Fernandez
    Division of Neurology, Hospital A Marcide, 15405 Ferrol, A Coruna, Spain
    Sci Eng Ethics 10:143-50. 2004
    ....
  50. ncbi request reprint "Stiff in the closet"--who provides care for Parkinsonian patients?
    A Jon Stoessl
    Can J Neurol Sci 29:203-4. 2002
  51. doi request reprint Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial
    William J Marks
    Department of Neurology, University of California, San Francisco, San Francisco, CA 94143 0138, USA
    Lancet Neurol 7:400-8. 2008
    ..The aim of this study was to assess the safety, tolerability, and potential efficacy of gene delivery of the neurotrophic factor neurturin...
  52. ncbi request reprint Progress in clinical neurosciences: a forum on the early management of Parkinson's disease
    Anthony E Lang
    Division of Neurology, Department of Medicine, University of Toronto, Toronto Western Hospital, Canada
    Can J Neurol Sci 32:277-86. 2005
    ..This report summarizes presentations and discussion dealing with these issues from a one-day symposium involving Canadian Movement Disorders neurologists...
  53. ncbi request reprint Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease
    Anthony E Lang
    Toronto Western Hospital, University of Toronto, Ontario, Canada
    Ann Neurol 59:459-66. 2006
    ..This randomized controlled clinical trial was designed to confirm initial clinical benefits observed in a small, open-label trial using intraputamenal (Ipu) infusion of recombinant human GDNF (liatermin)...
  54. doi request reprint Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease
    W R Wayne Martin
    Division of Neurology, University of Alberta, Edmonton, Alberta
    Ann Neurol 63:388-94. 2008
    ....
  55. ncbi request reprint Hot spots: can positron emission tomography offer insights into the pathogenesis of PD?
    A Jon Stoessl
    Ann Neurol 57:161-2. 2005
  56. ncbi request reprint Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2)
    Sarah Furtado
    Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
    Mov Disord 19:622-9. 2004
    ..This review emphasizes the importance of testing for SCA2 in patients with parkinsonism and a family history of neurodegenerative disorders. Testing for SCA2 is also important in studies of inherited parkinsonism...
  57. ncbi request reprint GDNF in treatment of Parkinson's disease: response to editorial
    Anthony E Lang
    Lancet Neurol 5:200-2. 2006
  58. ncbi request reprint Is there seasonal variation in risk of Parkinson's disease?
    Ronald B Postuma
    Department of Neurology, McGill University, Montreal General Hospital, Montreal, Quebec, Canada
    Mov Disord 22:1097-101. 2007
    ..We found no evidence of systematic seasonal variation in PD incidence by birth date, or of clustering of birth dates during influenza pandemic years in PD patients...
  59. ncbi request reprint Joubert syndrome surviving to adulthood associated with a progressive movement disorder
    Steven A Gunzler
    Parkinson s Disease Research, Education, and Clinical Center, Portland VA Medical Center, Portland, Oregon, USA
    Mov Disord 22:262-5. 2007
    ..This case demonstrates that a patient with Joubert syndrome may survive into adulthood and present as a chronic neurologic disorder with subacute extrapyramidal signs...